NASDAQ:AQST • US03843E1047
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AQUESTIVE THERAPEUTICS INC (AQST).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-07 | Lake Street | Maintains | Buy -> Buy |
| 2024-12-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-17 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-25 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-10-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-08 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-30 | Leerink Partners | Reiterate | Outperform -> Outperform |
| 2024-09-30 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-26 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | Leerink Partners | Initiate | Outperform |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 50.583M 6.09% | 57.561M 13.80% | 44.545M -22.61% | 50.885M 14.23% | 80.582M 58.36% | 175.66M 117.99% | 171.24M -2.52% | 264M 54.17% | 295.29M 11.85% | 417.79M 41.48% | 617.71M 47.85% | |
| EBITDA YoY % growth | -13.757M 65.33% | -30.053M -118.46% | -70.503M -134.60% | -57.392M 18.60% | -45.9M 20.02% | 40.086M 187.33% | 46.512M 16.03% | 173.2M 272.38% | 217.16M 25.38% | N/A | N/A | |
| EBIT YoY % growth | -15.102M 64.10% | -30.771M -103.75% | -71.051M -130.90% | -58.494M 17.67% | -42.965M 26.55% | 32.692M 176.09% | 5.686M -82.61% | 51.424M 804.40% | -102K -100.20% | 91.698M 90,000.00% | 249.7M 172.31% | |
| Operating Margin | -29.86% | -53.46% | -159.50% | -114.95% | -53.32% | 18.61% | 3.32% | 19.48% | -0.03% | 21.95% | 40.42% | |
| EPS YoY % growth | -0.36 68.42% | -0.52 -44.44% | -0.67 -28.85% | -0.59 12.57% | -0.41 29.19% | -0.02 95.08% | 0.21 1,150.00% | N/A | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 41.72% | -0.18 -26.77% | -0.16 -16.57% | -0.14 6.50% |
| Revenue Q2Q % growth | 11.114M 27.45% | 13.81M 38.06% | 17.603M 37.45% | 22.501M 72.89% |
| EBITDA Q2Q % growth | -10.914M 43.23% | -21.615M -94.92% | -19.259M -74.11% | -17.688M 37.48% |
| EBIT Q2Q % growth | -15.003M 22.53% | -20.431M -79.72% | -19.646M -71.14% | -17.463M 39.45% |
All data in USD
15 analysts have analysed AQST and the average price target is 9.41 USD. This implies a price increase of 134% is expected in the next year compared to the current price of 4.02.
AQUESTIVE THERAPEUTICS INC (AQST) will report earnings on 2026-05-11, after the market close.
The consensus EPS estimate for the next earnings of AQUESTIVE THERAPEUTICS INC (AQST) is -0.14 USD and the consensus revenue estimate is 11.11M USD.
The consensus rating for AQUESTIVE THERAPEUTICS INC (AQST) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.